Ionis Pharmaceuticals, Inc. | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Founded in 1989 and based in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biotechnology leader specializing in RNA-targeted therapeutics, with a major focus on antisense oligonucleotides (ASOs) for treating serious diseases such as neurology and cardiology disorders. Initially named Isis Pharmaceuticals, Ionis achieved industry milestones, including the FDA's approval of Vitravene in 1998—the first antisense drug—and the development of SPINRAZA, which transformed spinal muscular atrophy from a fatal disease into a manageable condition.

Ionis's proprietary ASO technology leverages RNA modulation to control gene expression, resulting in substantial advances in ASO chemistry and a robust pipeline of investigational RNA-targeted medicines. Operating under a fully integrated model, the company independently launches products while forging strategic partnerships with organizations like Biogen and AstraZeneca for late-stage development and commercialization. This approach accelerates market access and maximizes the impact of their innovative therapies.